|Mr. Geoff MacKay||Co- Founder, Pres, CEO & Director||746.7k||N/A||1966|
|Mr. Erik Ostrowski M.B.A.||CFO & Treasurer||739.58k||N/A||1973|
|Mr. Steven N. Avruch J.D.||Chief Legal Officer & Sec.||441.68k||N/A||1961|
|Mr. Jeffrey Medin Ph.D.||Scientific Founder||N/A||N/A||N/A|
|Mr. Matthew Arnold||Head of Operations||N/A||N/A||N/A|
|Mr. Kim Raineri M.B.A.||Chief Manufacturing & Technology Officer||N/A||N/A||N/A|
|Dr. Christopher Mason||Chief Scientific Officer||N/A||N/A||1959|
|Ms. Monique Da Silva||Sr. VP of Corp. Communications||N/A||N/A||N/A|
|Ms. Georgette Verdin||Chief HR Officer||N/A||N/A||N/A|
|Ms. Deanna M. Petersen M.B.A., MBA||Chief Bus. Officer||N/A||N/A||1962|
AVROBIO, Inc., a clinical-stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose in the United States. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene, which is defective in the target disease. The company's lead product candidate is AVR-RD-01, which is in ongoing Phase II clinical trial and investigator-sponsored Phase I clinical trial for the treatment of Fabry disease. It is also developing AVR-RD-02 that has completed pre-clinical trials for the treatment of type 1 Gaucher disease; AVR-RD-03, which is in preclinical development to treat Pompe disease; and AVR-RD-04 that has completed pre-clinical studies for treating cystinosis. The company has a research and clinical collaboration agreement with Magenta Therapeutics to evaluate targeted antibody-drug conjugate as a conditioning regimen for lentiviral gene therapies. AVROBIO, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
AVROBIO, Inc.’s ISS Governance QualityScore as of December 3, 2020 is 9. The pillar scores are Audit: 10; Board: 8; Shareholder Rights: 8; Compensation: 9.